COPENHAGEN, Jan 17 (Reuters) - Novo Nordisk
said on Friday that a late-stage trial with 7.2 milligram (mg)
of semaglutide, a high-dose version of the active ingredient
used in its blockbuster obesity drug Wegovy, helped overweight
patients cut their weight by 20.7%.